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1. Introduction 
Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease (IBD) affecting the 
colonic mucosa; it is of unknown etiology (Baumgart & Carding, 2007). UC clinically displays 
bloody diarrhea, abdominal pain and weight loss, and often leads to a severe outcome since 
the therapeutic approaches, including corticosteroid and 5-aminosalicylic acid, are not always 
successful in inducing long-term remission (Baumgart & Sandborn, 2007). Although the 
incidence of UC varies from 1 to 15 per 100,000 population in different locations, it increases 
year by year. Moreover, UC generally acts upon young people, and approximately 30% of 
patients with UC will undergo colectomy in the course of their life-times (Stewenius et al., 
1996). Thus, UC is a serious disease affecting the quality of life for a long period.  
It is now considered that IBD is not a simple inflammatory disease but a rather complicated 
disorder of intestinal components including epithelial cells, immune cells, neural cells, and 
extracellular matrix. Particular types of microbes, environmental factors including sanitary 
conditions and food, and genetic factors are also suggested to be involved (Xavier & Podolsky, 
2007; Kaser et al., 2010;Asakura & Suzuki, 2010). Global approaches are therefore needed to 
reveal the pathogenesis of IBD, and to develop new therapeutic approaches for IBD as well.  
Chemokines have taken great attention since their discovery, because this family of 
chemotactic cytokines is intimately involved in the pathogenesis of many important human 
diseases. Developing new therapeutic approaches targeting several chemokines have been 
tried (Viola & Luster, 2008).  
In this chapter, we will review the role of interferon-γ-inducible protein (IP)-10 (IP-
10/CXCL10) in the colon of normal condition and UC, introducing our recent findings 
about the effect of neutralization of IP-10 on animal models of UC. We also discuss about 
the possibility of clinical application of antagonist therapies targeting IP-10.   
2. Chemokines and chemokine receptors 
Chemokines are small 8-12 kDa proteins with 20 to 70 percent homology in amino acid 
sequence, are relatively resistant to inactivation, and have a long half-life in vivo (Rossi & 
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Zlotnik, 2000). They can direct the recruitment and migration of circulating leukocytes and 
play a critical role in the differentiation of secondary lymphoid organs. At present 
approximately 50 chemokines and 20 chemokine receptors are known. The chemokine 
system is characterized by redundancy (Mantovani,1999). A single chemokine can interact 
with several different chemokine receptors and a single chemokine receptor can respond to 
multiple chemokines. No chemokine is uniquely active on one leukocyte population, and 
usually a given leukocyte population has receptors for and responds to different molecules.   
 
 
Fig. 1. Chemokines and chemokine receptors 
Chemokines are classified into four families on the basis of the pattern of the first two of 
four cysteine residues of the ligands (Rossi & Zlotnik, 2000). The CXC family (α chemokine) 
has two cysteine residues separated by a non-cysteine amino acid. The CC family (β 
chemokine) contains two adjacent cysteine residues. The CX3C family (γ chemokine) has 
two cysteine residues separated by three non-cysteine amino acids, whereas the C family (δ 
chemokine) has only one cysteine residue. 
Chemokine receptors are G-protein-coupled receptors possessing a seven transmembrane 
domain that upon binding to calcium influx and activation of several downstream targets 
including the PI3 kinase pathway (Rossi & Zlotnik, 2000). Based on the chemokine class they 
bind, the receptors have been named CXCR1, 2, 3, 4 and 5 (bind CXC chemokines); CCR1 
through CCR10 (bind CC chemokines); XCR1 (binds the C chemokine, Lymphotactin); and 
CX3CR1 (binds the CX3C chemokine, fractalkine or neurotactin). 
Schematically, CXC chemokines are active on polymorphonuclear neutrophis (PMNs) and T 
and B cells. IL-8 is a typical CXC chemokine that acts on PMNs.  An essential structural 
element of CXC chemokine for neutrophil activation is a Glu-Leu-Arg (ELR) motif in the 5’-
structure of the protein. Thus CXC chemokines are divided into two groups; ELR motif 
chemokine and non-ELR motif chemokine.  In contrast, CC chemokines exert their action on 
multiple leukocyte subtypes, including monocytes, basophils, eosinophils, T cells, dendritic 
cells and natural killer (NK) cells, but they are generally inactive on PMNs. The 
representative CC chemokines, eotaxins, are active selectively on eosinophils and basophils. 
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Lymphotactin is a C chemokine, and fractalkine is a CX3C chemokine. They both act on T 
cells and NK cells, and fractalkine is also active on monocytes. 
Thus chemokines facilitate leukocyte migration and positioning to sites of tissue damage as 
well as other process such as angiogenesis and leukocyte degradation (Mackay, 2001). 
Chemokines and their receptors also important in dendritic cell maturation, B and T cell 
development, Th1 and Th2 responses, infections, angiogenesis, wound healing  and tumor 
growth as well as metastasis (Rossi & Zlotnik, 2000).  
Chemokines can be divided into two categories: inducible inflammatory chemokines are 
produced by activated cells and recruit leukocytes in response to physiological stress, 
whereas homeostatic chemokines are constitutively produced and involved in maintaining 
basal leukocyte trafficking as well as the architecture of secondary lymphoid organs (Gerard 
& Rollins, 2001). 
Recent advance of clinical and basic research have revealed that several diseases are 
associated with inappropriate activation of the chemokine-chemokine receptor network, and 
they include cardiovascular disease, allergic inflammatory disease, transplantation, 
neuroinflammation, cancer and HIV-associated disease (Gerard, & Rollins, 2001). 
Unlike cytokines, which have pleiotropic effects, chemokines target specific leukocyte 
subsets and, in some settings, may only attract these cells without activating them. 
Antagonism of a single chemokine ligand or receptor would be expected to have a relatively 
circumscribed effect, thereby endowing the antagonism with a limited side effect profile 
(Gerard & Rollins, 2001; Viola & Luster, 2008; Nishimura et al., 2009). 
 
 
* modified from Viola & Luster, 2008 
Table 1. The type of inflammation and chemokine/chemokine receptor system 
3. Interferon-γ-inducible protein (IP)-10 and its receptor CXCR3 
Luster et al. initially identified human IFN-γ-inducible protein of 10 kDa (IP-10/CXCL10) as 
an early response gene  induced by IFN-γ in U937 cells (a monocyte-like cell line) (Luster et 
al, 1985). IP-10 is secreted by a diverse range of tissue under proinflammatory conditions 
(Nevelle et al., 1997; Farber, 1997). It is a key mediator of the interferon response, preferentially 
attracts activated Th1 lymphocytes to sites of inflammation, and is an inhibitor of angiogenesis 
(Taub et al., 1993). IP-10 is constitutively expressed at low levels in thymic, splenic, and lymph 
node stroma. However, its expression can be highly induced in endothelial cells, keratinocytes, 
fibroblasts mesangial cells, astrocytes, monocytes, and neutrophils by stimulation with IFN-α, 
IFN-β, IFN-γ, or LPS and in T cells by antigen activation.  
Type of
inflammation
Main
target cells
Chemokine Chemokine receptor
Acute 
inflammation
Neutrophil
Monocyte
CXCL1 (GROα), CXCL2 (GROβ), CXCL8 (IL-8)
CCL2 (MCP-1)
CXCR2, CXCR1
CCR2
Th1–type  
inflammation
Monocyte
Th1 cell
CD8+ T cell
B cell
CCL2 (MCP-1), CCL4 (MIP-1β),CCL5 (RANTES), CX3CL1(Fractalkine)
CXCL9 (Mig), CXCL10 (IP-10),  CXCL11 (I-TAC)
CCL3 (MIP-1αS), CCL4 (MIP-1β), CXCL9 (Mig), CXCL10 (IP-10)
CXCL13 (BCA-1)
CCR2, CCR5, CCR1, CCR3, CX3CR1
CXCR3
CCR5, CCR1, CXCR3
CXCR5
Th2-type           
inflammation
Th2 cell
Eosinophil
Mast cell
B cell
CCL17 (TARC), CCL22 (MDC), CCL1 (I-309)
CCL11 (Eotaxin), CCL26 (Eotaxin-3)
CCL2 (MCP-1), CCL11 (Eotaxin), CXCL10 (IP-10)
CXCL13 (BCA-1)
CCR4, CCR8
CCR3
CCR2, CCR3, CXCR3
CXCR5
Th17- type           
inflammation
Th17, DC CCL20 (MIP-3α) CCR6
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Dufour et al. have generated mice deficient in IP-10 by targeted gene deletion mutagenesis 
(Dufour et al., 2002). IP-10-/- mice showed no overt developmental or morphological 
abnormalities, and fertile. Immunophenotyping of leukocyte subsets were similar between 
wild-type and IP-10-/- mice. In contrast, immunological analysis revealed a role for IP-10 in 
both the generation of effector T cells and their delivery to sites of tissue inflammation. 
Although described above chemokines and chemokine receptors are redundant in their 
action on target cells (Mantovani, 1999), IP-10 is somewhat atypical, in that it specifically 
activates a single receptor, CXCR3 (Loetscher et al., 1996).  While CXCR3 binds two other 
interferon-γ-induced, angiostatic CXC chemokines: monokine induced by interferon-γ 
(Mig:CXCL9) and interferon-inducible T cell α chemoattractant (I-TAC; CXCL11) (Loetscher 
et al, 1996; Cole et al.,1998), it is becoming clear that they exhibit unique expression patterns 
in vivo, and several data support the concept that these three chemokines may have 
nonredundant function in vivo (Dufour et al., 2002; Khan et al, 2000).  Crystal structures of 
IP-10 revealed that IP-10 ‘s action may involve oligomerization of the protein, and that IP-10 
shares the ability to bind to cell surface glycosaminoglycan (GAGs) with most, if not all, 
chemokines (Swaminathan et al.,2003; Luster et al., 1995). Chemokine-GAG interactions can 
promote chemokine oligomerization (Hoogewerf et al., 1997)), and the formation of 
immobilized chemokine gradients (Tanaka et al.,1993) , which are likely to be important for 
chemokine action. 
It has been reported that the expression of IP-10 was elevated in several diseases such as UC 
(Uguccioni et al., 1999), hepatitis (Narumi et al, 1998), multiple slcerosis (Sorensen et al., 
2002), and Sjoegren’s syndrome (Ogawa et al., 2002), suggesting the involvement of IP-10 in 
the development of these diseases. 
4. IP-10 and other chemokines in ulcerative colitis 
UC is a chronic relapsing disease of unknown etiology with a prominent leukocyte infiltrate, 
which is confined to the mucosa and submucosa of the colon and contributes largely to the 
tissue damage (Baumgart & Carding, 2007; Xavier & Podolsky, 2007). The disease usually 
involves the rectum and extends proximally to involve all or part of the colon (Baumgart & 
Sandborn, 2007). Proximal spread occurs in continuity without areas of uninvolved mucosa. 
The affected regions exhibit a mixture of acute and chronic inflammatory aspects 
accompanied by massive infiltration of macrophages, neutrophils, eosinophils, T cells, and 
plasma cells. The neutrophils invade the epithelium, usually in the crypts, giving rise to 
cryptitis and, ultimately, to crypt abscess. The following two major histological findings 
suggest chronicity of UC (Friedman & Blumberg, 2010). The first is basal plasma cytosis; 
multiple basal lymphoid aggregates are observed in some patients. The second is the 
distorted crypt architecture of the colon; crypts may be bifid and reduced in number, often 
with a gap between the crypt bases and the muscularis mucosae. The immune system seems 
to be shifted to atypical Th2 dominance, with coexistence of Th1 response. 
The recruitment and activation of leukocytes in inflamed tissues is a complex process driven 
by chemokines and possibly other attractants that induces cell adhesion and locomotion 
(Luster, 1998). Chemokines may play a central role in UC because chemokines are relatively 
resitant to inactivation in vivo, compared with other chemoattractants such as leukotriene 
B4, N-formyl-methionyl-leucyl-phenylalanin, and peptide activating factor, which have 
shorter half-lives (MacDermott et al., 1998). Furthermore, chemokines are produced by a 
wide variety of different cell types after stimulation by proinflammatory cytokines. The 
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ability of chemokines to activate cells to produce destructive molecules also makes them 
excellent candidates to be involved in the perpetuation of UC (MacDermott et al., 1998). 
 
 
Fig. 2. Histological features and endoscopic findings of ulcerative colitis 
Studies have demonstrated that IL-8, MCP-1, and ENA-78 are highly expressed in the 
intestinal mucosa in areas of UC as well as Crohn disease. Neutrophils and macrophages in 
the inflamed intestine synthesize and secrete large amounts of chemokines in patients with 
UC. Increased chemokine expression has also been observed in colonic epithelial cells, 
endothelial cells and smooth muscle cells (MacDermott, 1999). 
Several studies have reported increased expression of IP-10 in the mucosa of patients with 
UC and pouchitis (Uguccioni, 1999; Helwig, 2004; Autschbach, 2002; Grimm & Doe, 1996). 
However, there is a controversy about the source of IP-10 in the colonic mucosa; whether 
epithelial cells or immune cells. Generally, IP-10 is secreted by neutrophils, monocytes, 
fibroblasts, keratinocytes, dendritic cells, and epithelial cells. Dwinell et al. and Shibahara et 
al. have reported that human intestinal epithelial cell lines produce chemoattractants 
including IP-10 for IEL, and such chemokine production is regulated by proinflammatory 
cytokines such as IFN-γ (Dwinell et al., 2001, Shibahara et al., 2001). Intestinal subepithelial 
myofibroblasts have been also reported to produce IP-10 (Inatomi et al., 2005). 
5. IP-10 in animal models of IBD 
Mechanistic studies of IBD are difficult to perform in humans, hence animal models have 
been developed to analyse and develop new therapeutic approaches. 
Degeneration and necrosis of epithelial cells; 
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Plasma cells Crypt abscess 
(b) Endoscopic picture of ulcerative colitis.     
  In severe ulcerative colitis, macroulceration, 
occasionally deep, with mucopurulent exudate, 
pseudopolyposis, and spontaneous hemorrhage 
are seen. 
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IL-10-/- mice spontaneously develop colitis at ~ 3 months of age (Kuhn et al., 1993). This 
murine disease is similar to that seen in human Crohn disease with small intestine and colon 
disease localization, chronic mucosal inflammation, alterations in mucosal architecture, 
bowel-wall thickening, and a chronic progressive disease course. However, this murine 
model differs from human Crohn disease, because colitis in IL-10-/- mice does not yield focal 
granulomatous, or transmural inflammation. 
Singh et al. administered rabbit anti-IP-10 polyclonal IgG antibody to IL-10-/- mice by i.p. 
injection every 3 days at the onset of asymptomatic colitis (Singh, U.P. et al., 2003). They 
monitored serum amyloid A protein and IL-6 levels every other week, and determined the 
onset.  mRNA expression analysis shows upregulated IP-10 and CXCR3 in the inflamed colon 
of IL-10-/- mouse, while IP-10 is predominantly expressed in the mesenteric lymph nodes 
(MLNs). Neutralization of IP-10 ameliorated the severity of colitis along with decrease of SAA 
and several inflammatory cytokines. In their additional report, they showed that IP-10 is 
largely produced by CD4+ T cells in the mesenteric lymph nodes and lamina propria during 
colitis, and that IP-10 blockade decreased the number of CD4+ CXCL10+ cells in MLNs and 
lamina propria of IL10-/- mice (Singh et al., 2007).  These results suggest intestinal 
inflammation is driven by the presence of CD4+ CXCR3+ T cells and cells that produce IP-10. 
In confirmation, Hyun et al. have shown that anti-IP-10 antibody treatment can mitigate 
colitis in IL-10-/- mice through decreased trafficking of Th1 cells (Hyun et al, 2007) , with 
administration of  hamster antimurine CXCL10 monoclonal antibody (1F11).  They also 
revealed that CXCL10 blockade specifically decreased recruitment of transferred Th1 cells 
into MLNs and colon of IL-10-/- mice.  These data suggest that IP-10/CXCL10 plays a dual 
role in colitis development by enhancing Th1 cell generation in inductive sites (MLNs) and 
promoting effector cell recruitment to inflamed tissue (effector sites; colon).  
6. Our recent findings about IP-10 
IBD consists of two major forms: UC and Crohn disease. Crohn disease is suggested to be 
mediated by Th1/Th17-associated cytokines such as IL-23, IL-12, IL-17, and IFN-γ that are 
overproduced by macrophages and Th1/Th17 cells of the intestine (Strober & Fuss, 2011). 
Th17 cells are important in host defense against bacterial and fungal infections, in particular 
at mucosal surfaces (Ouyang, W. et al., 2008). Among many IBD animal models, colitis 
observed in both IL-10-/- mice and Rag2-/- mice reconstituted with CD4+CD45RBhighT cells 
has been characterized as a Th1/Th17-dependent disease, mimicking Crohn disease. 
In contrast, Th2-cytokines have been linked to UC, and UC is regarded as an atypical Th2 
disease with coexistence of Th1 type (Strober & Fuss, 2011). Okayasu et al. have reported a 
murine colitis model induced by administration of dextran sulphate sodium (DSS) as a 
model for UC (Okayasu et al., 1990). Additionally, we have esatablished a new chronic 
colitis using murine AIDS virus, which we termed MAIDS colitis, as a UC model (Suzuki et 
al.,1997).                      
Thus, to reveal the involvement of IP-10 in pathophysiology of UC, these two animal 
models; DSS colitis and MAIDS colitis, are ideal for mechanistic study using neutralizing 
anti-IP-10 antibody. 
6.1 Blockade of IP-10 ameliorated acute colitis and enhances crypt cell survival 
We have revealed that the endogenously produced chemokine IP-10 regulates crypt cell 
proliferation (Sasaki et al., 2002). IP-10 was constitutively expressed by basal crypts in 
www.intechopen.com
Role of Interferon-γ-Inducible Protein  
(IP)-10/ (IP-10/CXCL10) in Ulcerative Colitis; A Review of the Present Status 
 
109 
normal mouse colon, but the expression of IP-10 as well as CXCR3 was enhanced in the 
proliferative zone during acute phase of the colitis after oral administration of DSS. 
Neutralization of IP-10 with mouse monoclonal anti-IP-10 antibody protected mice from 
epithelial ulceration by promoting crypt cell survival without evidence of altered immune 
cell infiltration. Furthermore, recombinant IP-10 administration into normal mice inhibited 
intestinal epithelial cell proliferation. These findings suggest that IP-10 negatively regulates 
crypt cell growth to maintain intestinal homeostasis in an acute DSS colitis by enhancing 
crypt cell survival. 
Besides colonic crypt epithelial cells, IP-10 is also active on non-leukocytes/T cells such as 
endothelial cells and fibroblasts. Campanella et al. have recently reported that IP-10 can 
inhibit endothelial proliferation through a CXCR3-independent mechanism (Campanella et 
al., 2010). They speculate that the ability of IP-10 to inhibit endothelial  cell proliferation is 
more associated with its binding to glycosaminoglycans than its binding to CXCR3. 
We should further reveal the exact molecular mechanism how IP-10 could down regulate 
crypt cell proliferation. 
6.2 Blockade of IP-10 ameliorated pancreatitis-like injury of mice with MAIDS   
The LP-BM5 murine leukemia virus (MuLV) is a retrovirus that is known to induce 
profound immunodeficiency with splenomegaly and generalized lymphadenopathy in 
susceptible strains of mice, and occasionally brings about lymphoid malignancy (Mosier et 
al., 1985). Resembling the severe immunodeficiency with human acquired 
immunodeficiency syndrome (AIDS), the virus-infected mice have been studied as a mouse 
model of AIDS, termed murine AIDS (MAIDS) (Jolicoeur 1991). Based on the findings that 
systemic exocrinopathy resembling Sjoegren’s syndrome was induced in salivary glands 
and lacrimal glands as well as in the pancreas, we proposed that MAIDS mice could be an 
animal model for Sjoegren’s syndrome as well as AIDS (Suzuki et al., 1993). The pancreas-
infiltrating cells comprise both Th1 and Th2 type CD4+ T cells, although with a 
predominance of Th2 over Th1. Thus, the pancreatic lesions of MAIDS mice have some 
similarities to autoimmune-related chronic pancreatitis, especially the lesions associated 
with Sjoegren’s syndrome (Watanabe et al., 2003). 
We administered anti-IP-10 monoclonal antibody to MAIDS mice, and showed that anti-IP-
10 administration ameliorated the pancreatic lesions  by blocking the cellular infiltration of 
CD4+ T cells and IFN-γ+ Mac-1+ cells into the pancreas (Kawauchi et al., 2006).  
6.3 Blockade of IP-10 ameliorated MAIDS colitis 
Systemic exocrinopathy resembling Sjoegren’s syndrome and autoimmune pancreatitis-like 
pancreatic lesions were induced in mice with MAIDS, but colitis was not observed in 
MAIDS mice (Suzuki et al., 1993). In contrast, nude mice inoculated with lymph node cells 
from mice with MAIDS developed chronic inflammatory bowel disease-like colitis, which 
we termed MAIDS colitis (Suzuki et al., 1997). The precise mechanism of pathogenesis of the 
colitis remains largely unknown, however, regulatory T cells (Treg) deficiency might play a 
role in its development because there are some reports of colitis modulated by Treg (Izcue et 
al., 2006). We demonstrated that the pathological lesions of MAIDS colitis resembled 
ulcerative colitis and that the major populations of colon-infiltrating cells in MAIDS colitis 
were Mac1+ macrophages and CD4+ T cells with polarized immune responses toward Th2 
(Suriki et al., 2000). Thus, MAIDS colitis could serve as an animal model for UC. 
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Using our MAIDS colitis, we examined the effect of IP-10 blockade (Suzuki et al., 2007). 
Anti-IP-10 antibody treatment reduced the number of colon infiltrating cells when 
compared to those mice given a control antibody. The treatment made the length of the 
crypt of the colon greater than control antibody. The number of Ki67+ proliferating epithelial 
cells was increased by the anti-IP-10 antibody treatment. Terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labelling (TUNEL)+ apoptotic cells were observed in 
the epithelial cells of the luminal tops of crypts in control MAIDS colitis, whereas TUNEL+ 
apoptotic epithelial cells were rarely observed with anti-IP-10 antibody treatment. In 
summary, blockade of IP-10 attenuated MAIDS colitis through blocking cellular trafficking 
and protecting intestinal epithelial cells, suggesting that IP-10 plays a key role in the 
development of UC as well as in chronic MAIDS colitis. 
6.4 Our hypothesis of the role of IP-10 in UC, and theoretical therapeutic approach 
From our research findings about blockade of IP-10 for UC animal models, we propose the 
hypothesis of the role of IP-10 in UC as follows (Fig. 3.). 
In normal condition, naive T cells are activated by dendritic cells through IP-10 in 
mesenteric lymph nodes (inductive site) where they immediately express CXCR3 and 
differentiate into Th1 effector cells. IP-10 is constitutively expressed in normal colon, and 
promotes colonic recruitment of Th1 cells from blood vessels (Fig. 3a). Colonic epithelial cell 
regeneration and proliferation are regulated by a net balance between positive regulating 
factors and negative regulating factors (Podolsky, 1999). Several growth factors such as 
epidermal growth factor (EGF), keratinocyte growth factor (KGF), and hepatocyte growth 
factor (HGF) are typical positive regulating factors for intestinal epithelial proliferation and 
regeneration. They are secreted from both the local epithelial cells and the mesenchymal 
cells. In contrast, TGF-β is a typical negative regulator which inhibit proliferation of 
intestinal epithelial cells.  Additionally, as we described above, we found that IP-10 is 
another negative regulator of crypt epithelial proliferation (Sasaki et al., 2002). In normal 
intestine, the net balance between these two factors is well balanced, and normal intestinal 
epithelial renewing is maintained (Fig. 3a). 
In UC, IP-10 production is increased in both the mesenteric lymph nodes and the diseased 
colon, and more Th1 cells are differentiated and recruited into the effector site of colon (Fig. 
3b). In the colon of patients with UC, IP-10, a negative regulator for epithelial proliferation, 
is relatively over produced against positive regulators such as HGF (Fig. 3b). We have 
reported previously that intrinsic HGF is over produced in the colon of mice with DSS colitis 
(Hanawa, et al., 2006). In UC, net balance between positive and negative regulators are 
shifted toward negative ones, and colonic epithelial proliferation and regeneration are 
inhibited (Fig. 3b). 
Thus IP-10 plays two roles in the pathophysiology of UC: First, IP-10 is a chemokine 
which differentiates naive T cells into Th1 cells, and recruits them into the inflamed colon. 
Second, it is a negative regulator for intestinal epithelial proliferation and regeneration 
(Fig. 3b). 
Therefore, theoretically, blocking IP-10 is an ideal therapeutic approach for UC as we 
reported using two mouse models (Sasaki et al., 2002; Suzuki et al., 2007). 
We think that blockade of IP-10 promotes crypt epithelial cell proliferation and regeneration 
as well as inhibiting differentiation of Th1 cells and their trafficking into the diseased colon 
(Fig. 3c). 
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Fig. 3. Our hypothesis of the role of IP-10 in UC, and IP-10 blockade for UC therapy 
CXCR3 is a receptor for IP-10, and IP-10/CXCR3 axis plays a critical role in pathophysiology 
in several diseases including IBD (Singh et al., 2007; Groom & Luster, 2011). 
Several clinical trials using CXCR 3 antagonists are now under investigation for psoriasis, 
rheumatoid arthritis, and nephritis (Singh et al., 2007).  
CXCR3 respond not only for IP-10, but also for Mig and I-TAC. In addition, IP-10 exerts its 
effects through at least two systems such as CXCR3 and CXCR3-independent mechanism 
(Campanella et al., 2010).  
Therefore, we think that blockade of IP-10 using anti-human-IP-10 monoclonal antibody is a 
realistic strategy for the development of a new therapy targeting IP-10 for UC.    
7. Application of antagonist therapies targeting IP-10 for UC  
Chemokine and chemokine receptors are central to the inflammatory process and are 
attractive therapeutic targets. Several approaches are being pursued simultaneously, 
including antibodies to chemokines or their receptors, small molecule inhibitors of 
chemokine receptors modified chemokine antagonists, and inhibitors of chemokine 
presentation or higher-order structure (Viola & Luster, 2008). Schall and Proudfoot propose 
that inappropriate target selection and ineffective dosing, not the ‘redundancy’ of the 
chemokine system, are the main barriers to the use of chemokine receptor antagonists as 
anti-inflammatory therapies (Schall & Proudfoot, 2011).  
Recently, Phase 2, multi-dose, double-blind, placebo-controlled, randomized, multicenter 
study of MDX-1100 (anti-CXCL10 human monoclonal antibody) has been completed for 
patients with moderately-to-severely active UC (ClinicalTrials.gov  Web;  
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http://www.clinicaltrials.gov/ct2/show/NCT00656890?term=MDX-1100&rank=2).         
We are looking forward to seeing all the data about this proof-of-concept study. 
8. Conclusion 
As shown in this review, several important clinical and experimental data suggest that IP-10 
plays a critical role in the pathophysiology in UC, and it is an attractive therapeutic target. 
IP-10 is unique not only for its chemoattractant feature for activated Th1 cells, but also for its 
negative regulator activity for crypt epithelial cell cycle. Regulation of IP-10 could become a 
novel therapeutic approach for UC, which has both anti-inflammatory feature and 
facilitating ability of crypt epithelial cell regeneration. 
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